drugset / Trial / NCT06577155

Spinal Nalbuphine for Analgesia in Total Hip Arthroplasty

NCT06577155

RandomizedParallel-groupTriple-blindTreatment

Summary

60 patients ASA I-III, undergoing total hip arthroplasty were randomly assigned, into one of two groups, namely group E (n=30), where levobupivacaine will be administeral intrathecally ; and group N (n=30), where levobupivacaine plus nalbuphine will be administeral intrathecally. All patients will receive a standardized multimodal analgesic regimen, including a PENG block and PCA morphine. Morphine consumption during the first 24 hours postoperatively will be measured and additionally the investigators will record: Time of morphine first dose administration, NRS scores in static and dynamic conditions in 4 hours, 6 hours, 12 hours, 18 hours, 24 hours, 36 hours and 48 hours postoperatively, complications, patient satisfaction and duration of hospitalization.

Timeline

Start
2024-08-29
Primary completion
2025-01-21
Completion
2025-01-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nalbuphine Small molecule Intrathecal
Comparator Levobupivacaine Other / unclassified Intrathecal

Indications

No indication recorded.